alpha-aminopyridine has been researched along with Chronic Bronchitis in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davies, A; Gibson, D; Kiff, C; Purkayastha, D; Ruiz, S; Varol, N | 1 |
| Carson, KA; Hansel, NN; Laube, BL; Paulin, LM; Sharpless, G | 1 |
| Antoniu, SA | 1 |
| Bolger, GB; Coricor, GE; Courville, CA; Dransfield, MT; Farris, RF; Lambert, JA; Li, Y; Mazur, MM; McNicholas, CM; Raju, SV; Rowe, SM; Smoot, LH; Tang, LP | 1 |
| Sinopal'nikov, AI | 1 |
| Bailey, WC; Bhatt, SP; Blalock, JE; Dransfield, MT; Gaggar, A; Gautney, J; Handley, G; Jackson, PL; King, RW; Viera, L; Wells, JM; Xu, X | 1 |
| Anzueto, A; Martinez, FJ; McIvor, A; Pizzichini, E; Rabe, KF; Rennard, SI; Sethi, S; Siddiqui, S; Zhu, H | 1 |
| Alagappan, VK; Anzueto, A; Martinez, FJ; McIvor, A; Miller, CJ; Pizzichini, E; Rabe, KF; Reisner, C; Rekeda, L; Rennard, SI; Sethi, S; Siddiqui, S; Zetterstrand, S | 1 |
| Kelly Freeman, ML | 1 |
| Pham, NT; Reid, DJ | 1 |
2 review(s) available for alpha-aminopyridine and Chronic Bronchitis
| Article | Year |
|---|---|
[Novel trends in pharmacotherapy of chronic obstructive pulmonary disease--prevention of exacerbations (focus on roflumilast)].
Topics: Aminopyridines; Benzamides; Bronchitis, Chronic; Controlled Clinical Trials as Topic; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
Roflumilast: a novel treatment for chronic obstructive pulmonary disease.
Topics: Aminopyridines; Benzamides; Bronchitis, Chronic; Cyclopropanes; Forced Expiratory Volume; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2012 |
4 trial(s) available for alpha-aminopyridine and Chronic Bronchitis
| Article | Year |
|---|---|
Mucociliary Clearance in Former Tobacco Smokers with Both Chronic Obstructive Pulmonary Disease and Chronic Bronchitis and the Effect of Roflumilast.
Topics: Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Mucociliary Clearance; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Reproducibility of Results; Tobacco Smoking | 2019 |
A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.
Topics: Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Cyclopropanes; Double-Blind Method; Epoxide Hydrolases; Exercise Tolerance; Female; Forced Expiratory Volume; Glycine; Humans; Inflammation; Male; Middle Aged; Neutrophils; Phosphodiesterase 4 Inhibitors; Proline; Prolyl Oligopeptidases; Pulmonary Disease, Chronic Obstructive; Quality of Life; Serine Endopeptidases; Signal Transduction; Spirometry; Sputum; Treatment Outcome; Vital Capacity | 2015 |
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Budesonide, Formoterol Fumarate Drug Combination; Cyclopropanes; Disease Progression; Double-Blind Method; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Research Design; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity | 2016 |
Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Respiratory Therapy; Severity of Illness Index | 2016 |
4 other study(ies) available for alpha-aminopyridine and Chronic Bronchitis
| Article | Year |
|---|---|
Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK.
Topics: Administration, Inhalation; Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Hospitalization; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; United Kingdom | 2018 |
Phenotype/endotype-driven therapy in COPD: potential economic implications.
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Costs; Forced Expiratory Volume; Humans; Lung; Patient Selection; Phenotype; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Treatment Outcome | 2013 |
Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.
Topics: Aminophenols; Aminopyridines; Animals; Benzamides; Bronchi; Bronchitis, Chronic; Cells, Cultured; Cyclic AMP; Cyclopropanes; Cystic Fibrosis Transmembrane Conductance Regulator; Diarrhea; Dose-Response Relationship, Drug; Epithelial Cells; Humans; Intestinal Secretions; Intestine, Small; Membrane Potentials; Mice; Mucociliary Clearance; Phosphodiesterase 4 Inhibitors; Quinolones; Smoke; Smoking; Time Factors | 2014 |
Clinical Considerations for Roflumilast: A New Treatment for COPD.
Topics: Administration, Oral; Aminopyridines; Benzamides; Bronchitis, Chronic; Cyclic AMP; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2012 |